Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

(2021) Ralf‐Dieter Hofheinz et al.   INTERNATIONAL JOURNAL OF CANCER

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

(2019) Charles S Fuchs et al.   LANCET ONCOLOGY

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Antiangiogenic Therapy in Colorectal Cancer

(2018) Kabir Mody et al.   CANCER JOURNAL

Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma

(2018) C. Mariette et al.   Gastric Cancer

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

(2017) David Cunningham et al.   LANCET ONCOLOGY

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

(2016) H. H. Yoon et al.   ANNALS OF ONCOLOGY

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

(2016) Peter C. Enzinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

(2016) Salah-Eddin Al-Batran et al.   LANCET ONCOLOGY

NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors

(2015) Christoph Schulz et al.   INTERNATIONAL JOURNAL OF CANCER

Utility of the Proximal Margin Frozen Section for Resection of Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative

(2014) Malcolm H. Squires et al.   ANNALS OF SURGICAL ONCOLOGY

Is It Time to Abandon the 5-cm Margin Rule During Resection of Distal Gastric Adenocarcinoma? A Multi-Institution Study of the U.S. Gastric Cancer Collaborative

(2014) Malcolm H. Squires III et al.   ANNALS OF SURGICAL ONCOLOGY

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

(2014) Bo Hultman et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

The distance of proximal resection margin dose not significantly influence on the prognosis of gastric cancer patients after curative resection

(2014) Min Gyu Kim et al.   Annals of Surgical Treatment and Research

Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction

(2013) S. Mine et al.   BRITISH JOURNAL OF SURGERY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel

(2011) Nils Homann et al.   INTERNATIONAL JOURNAL OF CANCER

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: Results from a chinese mono-institutional study

(2011) Cheng-Gang Jiang et al.   JOURNAL OF SURGICAL ONCOLOGY

S3-Leitlinie „Magenkarzinom” -

(2011) M. Moehler et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE